31.32
+3.09%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genscript Biotech
Its shares trade on HKEX under the ticker 1548.HK. It has been listed since 30 December 2015. In the fiscal year to 31 December 2025, it reported revenue of $959.5m and a net loss of $532.8m. At that date it held total assets of $4.85bn and shareholders' equity of $3.96bn.
Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2015-12-30. The firm operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 30 Dec 2015
- Employees
- 3,973
- Website
- genscript.com ↗
Leadership
Pay as last reported
- Mr. Jiange MengExecutive Chairman of the Board, since 2010$531,000
- Ms. Ye WangPresident, Co-Founder, Executive Director, since 2015$914,000
- Ms. Weihui ShaoChief Executive Officer$3.6m
- Mr. Shiniu WeiChief Financial Officer
- Dr. Fangliang ZhangExecutive Director, since 2015$611,000
- Dr. Li ZhuExecutive Director, Chief Strategy Officer, since 2010$384,000
- Ms. Wai Ling WongCompany Secretary
- Mr. Yiu Leung CheungNon-Executive Independent Director$60,000
- Dr. Alphonse GaldesNon-Executive Independent Director$30,000
- Dr. Ross GrossmanNon-Executive Independent Director$23,000
- Mr. Jiuan PanNon-Executive Independent Director$86,000
- Dr. John QuelchNon-Executive Independent Director$11,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 86
- Environment
- 98
- Social
- 99
- Governance
- 63
- Direct emissions (scope 1)
- 39,376.8 t
- Energy emissions (scope 2)
- 112,287.37 t
- Value chain emissions (scope 3)
- 387,028 t
- Women in the workforce
- 58.49497%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Leading Biotech Company: GenScript Biotech Corp is a renowned biotech company known for its expertise and innovative solutions in the industry.
- Established Brand: The company has a strong brand presence globally, with a reputation for quality products and services.
- Diverse Product Portfolio: GenScript offers a wide range of biotech products and services, catering to the needs of customers from various sectors.
Weaknesses
- Dependency on Research and Development: GenScript's success heavily relies on continuous research and development efforts, making it susceptible to any disruptions in these processes.
- Vulnerability to Market Fluctuations: As a player in the biotech industry, GenScript is affected by market volatility, regulatory changes, and economic conditions, which may impact its financial stability.
- Limited Geographic Presence: Although GenScript operates globally, its reach may be limited in certain countries, potentially hindering expansion opportunities.
Opportunities
- Growing Demand for Biotech Solutions: The global biotech market is experiencing significant growth, providing opportunities for GenScript to capitalize on the increasing demand for its products and services.
- Mergers and Acquisitions: GenScript can explore strategic partnerships, mergers, or acquisitions to expand its market presence, acquire new technologies, and gain a competitive edge.
- Emerging Markets: Targeting emerging markets with high growth potential, such as Asia-Pacific and Latin America, can provide GenScript with new customers and revenue streams.
Threats
- Intense Competition: The biotech industry is highly competitive, with numerous players vying for market share. Increased competition can pose challenges for GenScript in maintaining its market position.
- Regulatory Risks: Adhering to complex and evolving regulations across different countries poses a potential risk for GenScript, as non-compliance could lead to penalties and reputational damage.
- Technological Advancements: Rapid technological advancements in the biotech field can impact GenScript's offerings, making it crucial for the company to stay at the forefront of innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.